Boston Scientific Cardiovascular — Cost of products sold increased by 12.3% to $1.04B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 15.5%, from $904.00M to $1.04B. Over 3 years (FY 2022 to FY 2025), Cardiovascular — Cost of products sold shows an upward trend with a 14.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Rising costs relative to sales may indicate supply chain inefficiencies or increased manufacturing expenses.
Includes the direct costs associated with manufacturing and delivering cardiovascular medical devices, such as raw mater...
Standard 'Cost of Goods Sold' (COGS) metric for manufacturing segments.
bsx_segment_cardiovascular_cost_of_products_sold| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $659.25M | $659.25M | $659.25M | $659.25M | $701.25M | $701.25M | $701.25M | $701.25M | $811.00M | $851.00M | $838.00M | $904.00M | $925.00M | $1.05B | $930.00M | $1.04B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +6.4% | +0.0% | +0.0% | +0.0% | +15.7% | +4.9% | -1.5% | +7.9% | +2.3% | +13.1% | -11.1% | +12.3% |
| YoY Change | — | — | — | — | +6.4% | +6.4% | +6.4% | +6.4% | +15.7% | +21.4% | +19.5% | +28.9% | +14.1% | +22.9% | +11.0% | +15.5% |